aTYR PHARMA INC (ATYR): R&D Expense
$60.22M
Year ended 2025-12-31
$47.09M
Trailing 12 months to 2026-06-30
+12.0%
3-year compound annual growth
+28.3%
5-year compound annual growth
+5.7%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $60.22M | +10.8% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $54.37M | +28.6% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $42.29M | -1.2% | 2026-03-05, From 2023-01-01 |
| 2022-12-31 | $42.81M | +84.0% | 2025-03-13, From 2022-01-01 |
| 2021-12-31 | $23.26M | +34.5% | 2024-03-14, From 2021-01-01 |
| 2020-12-31 | $17.29M | +23.1% | 2023-03-14, From 2020-01-01 |
| 2019-12-31 | $14.05M | -31.1% | 2022-03-15, From 2019-01-01 |
| 2018-12-31 | $20.39M | -32.2% | 2021-03-24, From 2018-01-01 |
| 2017-12-31 | $30.07M | -29.8% | 2020-03-26, From 2017-01-01 |
| 2016-12-31 | $42.85M | +24.2% | 2019-03-26, From 2016-01-01 |
| 2015-12-31 | $34.50M | +105.7% | 2018-03-20, From 2015-01-01 |
| 2014-12-31 | $16.78M | +21.3% | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | $13.83M | n/a | 2016-03-30, From 2013-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $60.22M | +10.8% |
| Zivo Bioscience, Inc. (ZIVO) | 2024-12-31 | $3.13M | +127.7% |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $4.19M | -16.6% |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | $3.92M | -36.7% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $35.33M | -4.1% |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $20.66M | -37.7% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $28.52M | -11.2% |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $6.00M | +33.5% |
| Prokidney Corp. (PROK) | 2025-12-31 | $114.12M | -10.6% |
Compare ATYR, ZIVO, VIVS, AIM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗